George Cowan, MD
Psychiatry · Florence, SCNPI 1740365691
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 222 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AbbVie at 57.3% of the total. Reporting peaked in 2023 at $706 and has fallen 53.4% since, to $329 in 2025.
Across 222 payments — averaging $9.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Axsome Therapeutics, Inc.$368
- Teva Pharmaceuticals USA, Inc.$200
- Takeda Pharmaceuticals U.S.A., Inc.$164
- Otsuka America Pharmaceutical, Inc.$38
- Vanda Pharmaceuticals Inc.$26
- plus $85 from 5 others
Across 4 payments — averaging $10,527 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$42K
What the payments were for
- Food & beverage$2,066100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 168 | $1,184 |
| Axsome Therapeutics, Inc. | 9 | $368 |
| Teva Pharmaceuticals USA, Inc. | 28 | $200 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $164 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Alkermes, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Almatica Pharma LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$208
How this compares
$2,066 in reported general payments places this provider in the 75th percentile of 624 psychiatry providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 15 | $89,565 |
| TrintellixVortioxetine Hydrobromide | 59 | $36,287 |
| CaplytaLumateperone Tosylate | 13 | $32,269 |
| LatudaLurasidone Hcl | 14 | $19,169 |
| AuvelityDextromethorphan Hbr/Bupropion | 13 | $13,998 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 18 | $9,203 |
| BelsomraSuvorexant | 14 | $5,953 |
| Modafinil | 39 | $5,174 |
| Aripiprazole | 37 | $2,536 |
| Bupropion XlBupropion Hcl | 85 | $2,415 |
| Methylphenidate ErMethylphenidate Hcl | 20 | $1,949 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 26 | $1,379 |
| Duloxetine Hcl | 40 | $1,373 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 42 | $1,325 |
| Prazosin Hcl | 33 | $995 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $200 | $89,56515 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $164 | $36,28759 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $18 | $32,26913 claims |
| Axsome Therapeutics, Inc.Auvelity | $368 | $13,99813 claims |
| Almatica Pharma LLCSertraline Hcl | $14 | $22224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 624 psychiatry providers in South Carolina.
Other psychiatry in Florence
- Veronica RidpathFlorence$364K
- Nikunjkumar ModiFlorence$133K
- Brittany AlbrightMount Pleasant$691K
- Jagdish ShahRock Hill$320K
- Ricardo FermoCharleston$262K
- John DewittAiken$221K
- Jeffrey StephensGreenville$195K
- Robert RichardsGreenville$142K
- Jacobo MintzerCharleston$132K
- Murray HonickMyrtle Beach$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.